[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Almirall, S.A.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":207},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,45,69,96,117,139,162,187],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100616896","phase-2-a-study-of-lad603-in-adults-with-alopecia-areata-100616896",false,"NCT07311564","A Study of LAD603 in Adults With Alopecia Areata","A Phase 2, Randomized, Placebo-controlled, Double-blind Clinical Study to Evaluate Efficacy and Safety of LAD603 in Adult Subjects With Severe to Very Severe Alopecia Areata","Inclusion Criteria:\n\n* Participant is a male or female between 18 and 65 years old at the time of signing the informed consent.\n* Severe to very severe AA criteria:\n\n  1. Greater than or equal to (\\>=) 50% hair loss of the scalp as measured by SALT without evidence of terminal hair regrowth within 6 months at both the Screening and Baseline (Day 1) visits.\n  2. Current episode of hair loss lasting at least 6 months and not exceeding 7 years.\n* Participants who are WOCBP or male must agree to the requirements for the avoidance of pregnancy and exposure of the participant's partner to LAD603 during the study,\n\nExclusion Criteria:\n\nAA, Skin Specific, and Other Inflammatory Diseases\n\n* Participants have other types of alopecia (including but not limited to traction, scarring alopecia).\n* Participants with \"diffuse\" type AA.\n* Currently has an active form of other inflammatory skin disease(s) or evidence of skin condition (e.g., psoriasis, seborrheic dermatitis, lupus) at the time of the Screening or Baseline (Day 1) visits that is expected to interfere with the assessment of alopecia areata severity.\n\nOther Medical Conditions\n\n* Participant has previous severe adverse reaction to subcutaneously administered medication.\n* Participant has any of the following liver safety laboratory results at Screening\n\n  1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than or equal to (\\>=) 2.5 × upper limit of normal (ULN)\n  2. Total bilirubin (TBL) \\>=1.5 × ULN (TBL \\>=3 × ULN in participants with Gilbert's syndrome)\n  3. Alkaline phosphatase (ALP) \\>=1.5 × ULN\n\n     Prior\u002FConcomitant Therapy\n* Intention to use any concomitant medication that is not permitted by this protocol or failure to undergo the required washout period for a particular prohibited medication.","ALL","18 Years","65 Years",{"count":20,"type":21},136,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA). The study will also evaluate the safety, pharmacokinetics (PK), immunogenicity and pharmacodynamic (PD) biomarkers of LAD603.",[27],"Alopecia Areata",[29,30,31],"Hair Loss","Hypotrichosis","Alopecia","RECRUITING","2026-05-19",{"date":35,"type":36},"2026-05-20","ACTUAL",{"date":38,"type":36},"2025-12-17",{"date":40,"type":21},"2027-11-21",{"name":42,"class":43},"Almirall, S.A.","INDUSTRY",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":44},"100629227","phase-1-a-study-of-lad106-in-healthy-adult-participants-100629227","NCT07471932","A Study of LAD106 in Healthy Adult Participants","A Phase 1, Randomized, Two-part, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity and Pharmacodynamics of LAD106 in Healthy Adult Participants","Inclusion Criteria:\n\n1. Signed informed consent and willing and able to comply with the study protocol.\n2. Healthy men or women,18 to 45 years of age (inclusive) at screening.\n3. Female participants agree to use effective contraception.\n4. Male volunteers agree to use barrier protection when they engage in sexual relations with women of child-bearing potential (WOCBP) or lactating women.\n5. Body mass index (BMI) between 18 and 32 kilograms per square meter (kg\u002Fm\\^2), inclusive, and with a minimum bodyweight of 50 kg.\n6. Has the ability to communicate well with the Investigator in Dutch language and willing to comply with the study restrictions.\n\nExclusion Criteria:\n\n1. Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would pose an unacceptable risk to the participant in the opinion of the investigator.\n2. Clinically significant abnormalities, as judged by the Investigator, in laboratory test results.\n3. Use of any medications (prescription or over-the-counter \\[OTC\\]), within 14 days prior to IMP dosing or less than 5 half-lives (whichever is longer). An exception is made for paracetamol (up to 4 g\u002Fday).\n4. If a woman, pregnant, or breast-feeding, or planning to become pregnant during the study.",true,"45 Years",{"count":55,"type":21},93,[57],"PHASE1","The main aim of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of single ascending doses of LAD106 (Part A) and multiple ascending doses of LAD106 (Part B) in human healthy participants.",[60],"Healthy Volunteers","2026-05-14",{"date":63,"type":36},"2026-05-15",{"date":65,"type":36},"2026-02-17",{"date":67,"type":21},"2027-05-31",{"name":42,"class":43},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":4},"100634653","phase-3-a-study-of-lebrikizumab-in-adults-with-nummular-eczema-100634653","NCT07542483","A Study of Lebrikizumab in Adults With Nummular Eczema","A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study With a Double-Blind Extension Evaluating Efficacy and Safety of Lebrikizumab Administered to Adult Patients With Nummular Eczema Who Are Not Adequately Controlled With Topical Corticosteroids or When This Treatment is Not Medically Advisable (LUMINE)","LUMINE","Inclusion Criteria:\n\nParticipants eligible for inclusion in this trial must fulfil all inclusion criteria per protocol, main criteria are listed below:\n\n* Ability to understand the purpose and risks of the trial, willingness and ability to comply with the protocol, and ability to provide written informed consent in accordance with institutional and regulatory guidelines.\n* Adult (aged 18 years or more at the time of Screening) diagnosed clinically with NE, as confirmed by the Investigator.\n* Presence of nummular eczema signs and\u002For symptoms for at least 6 months prior to Screening.\n* Investigator Global Assessment score \\>=3 at both Screening and Baseline\u002FDay 1 visits.\n* In the judgement of the Investigator, having inadequate response to TCS.\n\nExclusion Criteria:\n\nParticipants fulfilling any of the exclusion criteria per protocol are not eligible for inclusion in this trial main criteria are listed below:\n\n* Documented history or current presence of moderate-to-severe AD at the Screening visit, or documented diagnosis of moderate-to-severe AD from Screening to Baseline\u002FDay 1 visit (ie, EASI \\>=16).\n* Presence of any skin disease, other than NE or mild AD, that could interfere with assessment of the study outcomes, including but not limited to psoriasis and other forms of eczema (dyshidrotic eczema, stasis dermatitis, asteatotic eczema, and neurodermatitis).\n* Presence of any skin manifestations suggestive of psoriasis including but not limited to nail pitting, scalp, palms, soles, or skin folds involvement, as well as personal or family history of psoriasis or psoriatic arthritis.\n* Prior treatment at any time with lebrikizumab, dupilumab, tralokinumab, or oral Janus kinase inhibitor.\n* Treatment with an investigational drug within 8 weeks or within 5 half-lives (if known), whichever was longer, prior to Screening.\n* Intention to use any concomitant medication that is not permitted by this protocol or failure to undergo the required washout period for a particular prohibited medication.\n* History of anaphylaxis as defined by the Sampson criteria.\n* Uncontrolled chronic disease that might require multiple intermittent uses of systemic corticosteroids, eg, uncontrolled asthma.\n* Have had any of the following types of infection within 3 months of Screening or develop any of these infections before Baseline\u002FDay 1:\n\n  1. Serious (requiring hospitalisation and\u002For intravenous or equivalent oral antibiotic treatment, per the Investigator's opinion)\n  2. Opportunistic (as defined by Winthrop 2015) Note: herpes zoster is considered active and ongoing until all vesicles are dry and crusted over\n  3. Chronic (duration of symptoms, signs, and\u002For treatment of 6 weeks or longer), including hepatitis B virus and hepatitis C virus infections\n  4. Recurring (including but not limited to herpes zoster, recurring cellulitis, and chronic osteomyelitis) with the exception of uncomplicated herpes simplex infection, which is not considered exclusionary\n* Known liver cirrhosis and\u002For chronic hepatitis of any aetiology.\n* Diagnosed active endoparasitic infections or at high risk of these infections.\n* Known or suspected history of immunosuppression, including history of invasive opportunistic infections (eg, tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, and aspergillosis) despite infection resolution, or unusually frequent, recurrent, or prolonged infections, per the Investigator's judgement.\n* History of human immunodeficiency virus (HIV) infection or known positive HIV serology.\n* In the Investigator's opinion, any clinically significant laboratory test results from the chemistry or haematology tests obtained at the Screening visit.\n* History of malignancy, including mycosis fungoides\u002Fcutaneous T-cell lymphoma, within 5 years before the Screening visit, except for completely treated in situ carcinoma of the cervix or completely treated and resolved nonmetastatic squamous or basal cell carcinoma of the skin with no evidence of recurrence in the past 12 weeks.\n* Severe concomitant illness(es) that in the Investigator's judgement would adversely affect the participation in the study. Any other medical or psychological condition that in the opinion of the Investigator may suggest a new and\u002For insufficiently understood disease, may present an unreasonable risk to the study participant because of their participation in this clinical trial, may make participation unreliable, or may interfere with study assessments.\n* Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.\n* History of sensitivity and\u002For allergy to any of the ingredients of the trial medication.",{"count":78,"type":21},270,[80],"PHASE3","The main aim of the study is to evaluate the efficacy, safety, and tolerability of lebrikizumab treatment in adult participants with Nummular Eczema (NE) who are not adequately controlled with Topical corticosteroids (TCS) or when this treatment is not medically advisable.",[83],"Nummular Eczema",[83,85,86,87],"Dermatitis","Skin Diseases","Lebrikizumab","NOT_YET_RECRUITING","2026-05-13",{"date":61,"type":36},{"date":92,"type":21},"2026-04",{"date":94,"type":21},"2029-02",{"name":42,"class":43},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":44},"100604624","phase-2-a-study-of-lad191-in-adults-with-hidradenitis-suppurativa-100604624","NCT07151937","A Study of LAD191 in Adults With Hidradenitis Suppurativa","A Seamless Phase 2a\u002F2b, Randomized, Double-Blind, Placebo- and Active-Controlled, Multiple-Arm, Multiple-Stage, Adaptive Study Evaluating the Efficacy and Safety of LAD191 in Adults With Moderate-to-Severe Hidradenitis Suppurativa","Inclusion Criteria:\n\n* Aged greater than or equal to (\\>=) 18 to less than or equal to (\\\u003C=) 65 years.\n* A diagnosis of moderate-to-severe HS defined as a total of \\>= 5 inflammatory lesions (i.e., number of abscesses plus number of inflammatory nodules) at both the Screening and Baseline\u002FDay 1 visits, with signs and symptoms of HS for at least 6 months.\n* HS lesions present in at least 2 distinct anatomic areas (e.g., left and right axilla), one of which must be at least Hurley Stage II or Hurley Stage III at both the Screening and Baseline\u002FDay 1 visits.\n* History of inadequate response, intolerance, or contraindication to a course of a systemic antibiotics for treatment of HS at the screening visit.\n* Regular use of over-the-counter topical antiseptics on HS lesions and agrees to regular use, throughout the entirety of the study.\n* Participants who are women of child-bearing potential (WOBCP) and male participants must agree to the requirements for the avoidance of pregnancy and exposure of the participant's partner to LAD191 during the study.\n\nExclusion Criteria:\n\n* HS with \\>20 draining tunnels at the Screening or Baseline\u002FDay 1 visit.\n* Ongoing medical conditions requiring systemic immunosuppressive\u002Fimmunomodulating treatments during the study.\n* Known hypersensitivity to LAD191 or any of its excipients.\n* Known hypersensitivity to adalimumab or biosimilar or any of its excipients or meeting any warning or contraindication to adalimumab treatment as per the approved product information, and as per the Investigator's judgment.\n* Hypersensitivity or systemic reaction to a prior biologic (antibody-based) therapy, regardless of indication, that was clinically significant, as per the Investigator's judgment.\n* Prior treatment with LAD191.\n* Live or attenuated vaccinations 4 weeks prior to Baseline\u002FDay 1 or is planning to receive any such vaccine during the study.\n* Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.\n* Intention to use any concomitant medication or therapy that is not permitted by this protocol or failure to meet the required washout period for a particular prohibited medication prior to Baseline\u002FDay 1.",{"count":104,"type":21},200,[24],"The main purpose of this study is to assess the efficacy of multiple dosing regimens of LAD191 compared to placebo in participants with moderate-to-severe Hidradenitis Suppurativa (HS) and to access the safety, tolerability, pharmacokinetic and immunogenicity in participants with moderate-to-severe HS.",[108],"Hidradenitis Suppurativa","2026-05-07",{"date":111,"type":36},"2026-05-11",{"date":113,"type":36},"2025-11-05",{"date":115,"type":21},"2027-11-25",{"name":42,"class":43},{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":129,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":136,"leadSponsor":138,"locationsCount":4},"100635063","phase-2-a-proof-of-concept-study-of-lad328-in-adults-with-hidradenitis-suppurativa-100635063","NCT07547813","A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa","A Phase 2, Randomized, Placebo-controlled, Double-blind Clinical Study to Evaluate Efficacy and Safety of LAD328 in Adult Subjects With Moderate-to-Severe Hidradenitis Suppurativa","Inclusion Criteria:\n\n* Male or female between 18 and 65 years old inclusive.\n* A diagnosis of moderate-to-severe HS defined as a total of \\>=5 inflammatory lesions (i.e., number of abscesses plus number of inflammatory nodules) at both the Screening and Baseline visits, with a clinical history of HS for at least 6 months.\n* HS lesions present in at least 2 distinct anatomic areas (e.g., left and right axilla), one of which must be at least Hurley Stage II or Hurley Stage III at both the Screening and Baseline visits.\n* History of inadequate response, or intolerance or contraindication, to a course of a systemic antibiotics for treatment of HS at the Screening visit.\n* Agree to regularly use, over-the-counter topical antiseptics on their HS lesions throughout the entirety of the study.\n* Participants who are woman of child-bearing potential (WOCBP) and male participants must agree to the requirements for the avoidance of pregnancy and exposure of the participant's partner to LAD328 during the trial.\n\nExclusion Criteria:\n\n* HS with \\>20 draining tunnels either at the Screening or Baseline visits.\n* Ongoing medical conditions (e.g., inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus and sarcoidosis) requiring systemic immunosuppressive\u002Fimmunomodulating treatments (e.g., methotrexate, ciclosporin, corticosteroids, cytokine-targeted therapy and JAK inhibitors) during the trial.\n* Known or suspected hypersensitivity to trial product or any of its excipients.\n* Hypersensitivity or systemic reaction to a prior biologic (antibody-based) therapy (regardless of indication), that was clinically significant, as per judgment of Investigator.\n* Prior treatment with LAD328.\n* Live and attenuated vaccinations 4 weeks prior Pre-treatment or is planning to receive any such vaccine during the trial.\n* Females who are pregnant or breast-feeding or seeking to become pregnant during the trial.",{"count":125,"type":21},50,[24],"The main purpose of this study is to evaluate the effect of LAD328 compared to placebo in participants with moderate-to-severe Hidradenitis Suppurativa (HS), and to access the safety, tolerability, pharmacokinetic and immunogenicity in participants with moderate-to-severe HS.",[108],[130,86,131],"Hidradenitis","Infections","2026-04-17",{"date":134,"type":36},"2026-04-23",{"date":92,"type":21},{"date":137,"type":21},"2027-04",{"name":42,"class":43},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":44},"100578752","a-study-to-assess-the-impact-of-lebrikizumab-on-health-related-well-being-and-control-of-skin-manifestations-in-participants-with-moderate-to-severe-atopic-dermatitis-100578752","NCT06815380","A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants With Moderate-to-Severe Atopic Dermatitis","A European, Multicenter, Prospective Observational Phase IV Clinical Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Patients With Moderate-to-Severe Atopic Dermatitis","ADTrust","Inclusion Criteria:\n\n* Adult (greater than or equal to \\[\\>=\\] 18 years) male or female participants with diagnosis of moderate-to-severe Atopic dermatitis.\n* Adult participants prescribed lebrikizumab as part of routine\u002Fusual care to manage their moderate-to severe Atopic dermatitis.\n* Willingness and ability to participate in the study; participants must give their written consent to participate.\n\nExclusion Criteria:\n\n* Hypersensitivity to the active substances or to any of the excipients of lebrikizumab (Ebglyss®).\n* Participants with pre-existing helminth infections. These participants should be treated for helminth infection before starting lebrikizumab therapy.\n* Concomitant use of live and live attenuated vaccines.\n* Pregnant women, except when the potential benefit justifies the potential risk.\n* Participants included in a clinical trial at baseline or at any time during the planned study period.\n* Participants unable to comply with the requirements of the study or who, in the opinion of the study physician, should not participate in the study.\n* Participants for whom medical chart is inaccessible to physicians to complete baseline data collection.",{"count":148,"type":21},1000,"OBSERVATIONAL","The main purpose of this study is to evaluate the impact of lebrikizumab treatment on the overall well-being of adult participants with moderate-to-severe AD in real-world clinical practice settings across Europe, as measured using validated 5-item World Health Organization Well-being Index (WHO-5) and to investigate effectiveness and safety of lebrikizumab, treatment satisfaction, and long-term effect of lebrikizumab treatment on participants in terms of disease symptomatology\u002Fcontrol, fatigue, work impairment, patient's relationship with their skin, and overall QOL among adult participants.",[152,153],"Atopic Dermatitis","Eczema","2025-02-04",{"date":156,"type":36},"2025-02-07",{"date":158,"type":36},"2025-01-23",{"date":160,"type":21},"2029-03",{"name":42,"class":43},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":172,"conditions":173,"keywords":175,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":44},"100518339","a-study-of-tildrakizumab-in-the-treatment-of-genital-psoriasis-czatch-genital-pso-100518339","NCT06029257","A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)","Effectiveness and Safety of Tildrakizumab in the Treatment of Genital Psoriasis in Austria, Switzerland, and the Czech Republic","Inclusion Criteria:\n\n* Confirmed diagnosis of psoriasis, with significant involvement of genital regions, i.e., sPGA-G greater than or equal to (\\>=) 3.\n* Need for systemic biologic therapy based on the local country specific regulations. Tildrakizumab, in accordance with the SmPC, must be the anti-IL23p19 selected therapy before including the patient in the study.\n* Age 18 - 99 years.\n* Informed consent in writing in accordance with applicable country regulations\n* Patient must have plaque psoriasis affecting a body surface area (BSA) \\>= 1% in a non-genital area at baseline.\n* Patient willing and able to fill out study questionnaires.\n\nExclusion Criteria:\n\n* Patient appears to be unwilling or unable to comply with the requirements of the study or who, in the opinion of the investigator, should not participate in the study.\n* Patient exposed to any experimental treatment in the past 3 months prior to baseline.\n* Any condition preventing prescription of Tildrakizumab according to the SmPC, including but not restricted to any contraindication or history of hypersensitivity or intolerance.\n* Patient dependent on the investigator, including but not restricted to employees of the study site.\n* Previous treatment with Tildrakizumab.","99 Years",{"count":171,"type":21},110,"The main aim of this study is to check the safety and effectiveness of tildrakizumab regarding the alleviation of symptoms in the genital area after administration according to the summary of product characteristics (SmPC) and to access overall treatment safety and quality of life assessed on multiple scales.",[174],"Genital Psoriasis",[176,177,86,178],"Psoriasis","Plaque psoriasis","Tildrakizumab","2025-01-28",{"date":181,"type":36},"2025-01-29",{"date":183,"type":36},"2023-11-14",{"date":185,"type":21},"2026-03",{"name":42,"class":43},{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":201,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":44},"100518402","a-study-to-assess-the-effects-of-switching-from-a-biologic-treatment-to-tildrakizumab-using-patient-reported-outcomes-in-adult-participants-with-moderate-to-severe-plaque-psoriasis-100518402","NCT06030076","A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis","A Non-interventional, Prospective Cohort, Multicentre, Real-world Evidence Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis in Austria and Switzerland","Inclusion Criteria:\n\n1. Written informed consent.\n2. \\>=18 years of age.\n3. Moderate-to-severe plaque psoriasis currently treated with a biologic therapy (TNFα antagonist, IL12\u002F23 antagonist, IL17 antagonist).\n4. Switch to tildrakizumab due to:\n\n   1. primary or secondary treatment failure (PASI \\>= 3 or ΔPASI \\\u003C 75 and\u002For DLQI \\> 5)\n   2. adverse events, contraindication, intolerance\n   3. patient wish (dosing regimen), lack of adherence, or other, including nonmedical reason\n5. Treatment with tildrakizumab planned in the frame of clinical practice.\n\nExclusion Criteria:\n\n1. Patient appears to be unwilling or unable to comply with the requirements of the study or who, in the opinion of the Investigator, should not participate in the study.\n2. \\>=3 previous biologic treatments in the last 3 years.\n3. Participation in a clinical trial simultaneous to participation in SW-ATCH.\n4. Any condition preventing prescription of Tildrakizumab according to the SmPC, including but not restricted to any contraindication or history of hypersensitivity or intolerance.\n5. Patient dependent on the Investigator.\n6. Previous treatment with Tildrakizumab.",{"count":125,"type":21},"The main aim of this study is to assess the effects of switching from another biologic to tildrakizumab on patient-reported outcomes and to assess psoriasis intensity, patient's quality of life prior and after switching and the individual rationales for switching biologics.",[197],"Plaque Psoriasis",[176,178,199,200],"Moderate-to-severe plaque psoriasis","Prospective",{"date":181,"type":36},{"date":203,"type":36},"2023-09-06",{"date":205,"type":21},"2025-10",{"name":42,"class":43},""]